Medical/Pharmaceuticals
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026
Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...
2026-04-14 21:08
4074
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...
2026-04-14 21:02
4841
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...
2026-04-14 15:11
5489
Boston Aesthetics Appoints Brandon Nye as Chief Executive Officer to Drive Next Phase of Commercial Growth
IRVINE, Calif., April 13, 2026 /PRNewswire/ – Boston Aesthetics today announced the appointment of Brandon Nye as Chief Executive Officer, effective immediately. Nye will lead the company's strategic growth initiatives, commercial expansion, and operating execution as Boston Aesthetics enters its...
2026-04-13 23:00
4329
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...
2026-04-13 16:34
6620
Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain
BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...
2026-04-13 14:24
4823
SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH
NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...
2026-04-11 16:20
4923
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
* Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Vivatides Therapeutics, a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the s...
2026-04-10 20:00
5693
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led...
2026-04-10 08:00
5509
NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan
SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has entered into an exclusive distribution agreement in Japan with Asahi Intecc Co., Ltd., a global medical device compan...
2026-04-09 21:00
5318
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", also known as DB-1303 or BNT323), has been ...
2026-04-09 19:55
6027
Portrai to Present 11 Posters on AI-Driven Spatial Transcriptomics at AACR 2026
The South Korean spatial biology company unveils new AI agents, foundation models, and spatial biomarkers for oncology drug discovery. SEOUL, South Korea, April 8, 2026 /PRNewswire/ -- Portrai, Inc. today announced it will present 11 posters highlighting its artificial intelligence and spatial t...
2026-04-08 17:50
3861
ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation
SHANGHAI, April 7, 2026 /PRNewswire/ -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the...
2026-04-08 14:08
3777
Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China
BEIJING, April 7, 2026 /PRNewswire/ -- Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology, inflammation, and autoimmune diseases, today announced that the first patient has been dosed...
2026-04-07 21:00
3558
Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has receive...
2026-04-07 19:00
3718
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II ...
2026-04-07 11:28
5104
Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
* By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ ...
2026-04-06 20:00
GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
* Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology * Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks YONGIN, South Korea, April 6...
2026-04-06 14:28
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (Nasdaq: RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ...
2026-04-04 00:00
8079
Assembling Over 1,000 Human Genomes Affordably: New Method Powers Medicine's Future
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A research team led by Zhen-Xing Endowed Professor Jian Yang at the School of Life Sciences, Westlake University, together with collaborators, published their latest findings in Nature on April 1. The study innovatively developed a pangenome-informed...
2026-04-03 19:32
3962
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 291 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 290 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
